David Andrew Shaywitz, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Product Surveillance, Postmarketing | 1 | 2019 | 452 | 0.470 |
Why?
|
| Biotechnology | 2 | 2007 | 282 | 0.470 |
Why?
|
| Research Personnel | 3 | 2007 | 588 | 0.430 |
Why?
|
| Drug Industry | 3 | 2007 | 788 | 0.400 |
Why?
|
| Information Dissemination | 1 | 2019 | 1126 | 0.360 |
Why?
|
| Gastroparesis | 2 | 2021 | 136 | 0.320 |
Why?
|
| Career Mobility | 2 | 2007 | 259 | 0.300 |
Why?
|
| Technology Transfer | 1 | 2007 | 42 | 0.290 |
Why?
|
| Entrepreneurship | 1 | 2005 | 23 | 0.260 |
Why?
|
| Growth and Development | 1 | 2005 | 47 | 0.250 |
Why?
|
| Spouses | 1 | 2006 | 283 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2007 | 3429 | 0.210 |
Why?
|
| Fungal Proteins | 2 | 1997 | 910 | 0.200 |
Why?
|
| Conflict of Interest | 1 | 2006 | 554 | 0.190 |
Why?
|
| Drug Discovery | 1 | 2009 | 1051 | 0.190 |
Why?
|
| Congresses as Topic | 1 | 2006 | 803 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 8000 | 0.150 |
Why?
|
| Coated Vesicles | 1 | 1997 | 23 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2225 | 0.150 |
Why?
|
| Periodicals as Topic | 3 | 2006 | 1463 | 0.140 |
Why?
|
| Medical Errors | 1 | 2004 | 1260 | 0.130 |
Why?
|
| Medicine | 1 | 2004 | 941 | 0.130 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 1997 | 200 | 0.130 |
Why?
|
| International Cooperation | 1 | 2002 | 1422 | 0.130 |
Why?
|
| Physician's Role | 1 | 2002 | 916 | 0.130 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1664 | 0.130 |
Why?
|
| Research | 2 | 2002 | 1977 | 0.130 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 389 | 0.110 |
Why?
|
| Industry | 2 | 2006 | 364 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 3612 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 2 | 1997 | 1134 | 0.100 |
Why?
|
| Malaria | 1 | 2002 | 1227 | 0.100 |
Why?
|
| Developing Countries | 2 | 2002 | 2885 | 0.100 |
Why?
|
| Education, Medical | 2 | 2002 | 1725 | 0.100 |
Why?
|
| Research Support as Topic | 2 | 2006 | 697 | 0.100 |
Why?
|
| Biology | 2 | 2005 | 289 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1997 | 1841 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2000 | 1422 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2002 | 2016 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 1997 | 7856 | 0.080 |
Why?
|
| Physicians | 1 | 2007 | 4591 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 1997 | 2448 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2007 | 11526 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 2 | 2009 | 1088 | 0.070 |
Why?
|
| Consultants | 1 | 2006 | 56 | 0.070 |
Why?
|
| Endoderm | 1 | 2007 | 160 | 0.070 |
Why?
|
| Utah | 1 | 2006 | 131 | 0.070 |
Why?
|
| Nuclear Pore Complex Proteins | 2 | 1997 | 163 | 0.060 |
Why?
|
| Publishing | 2 | 2002 | 833 | 0.060 |
Why?
|
| Happiness | 1 | 2006 | 170 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1997 | 4936 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 793 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2006 | 786 | 0.050 |
Why?
|
| GTP-Binding Proteins | 2 | 1997 | 951 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2006 | 458 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2001 | 123 | 0.050 |
Why?
|
| Disclosure | 1 | 2006 | 748 | 0.040 |
Why?
|
| Universities | 1 | 2005 | 993 | 0.040 |
Why?
|
| United States | 3 | 2019 | 72339 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 1263 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2021 | 242 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1997 | 2188 | 0.040 |
Why?
|
| COP-Coated Vesicles | 1 | 1997 | 39 | 0.040 |
Why?
|
| Science | 1 | 2000 | 239 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 2 | 1997 | 471 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 1997 | 405 | 0.030 |
Why?
|
| HIV Infections | 1 | 2002 | 17347 | 0.030 |
Why?
|
| World Health Organization | 1 | 2002 | 1316 | 0.030 |
Why?
|
| Humans | 11 | 2021 | 761423 | 0.030 |
Why?
|
| Specialization | 1 | 2000 | 779 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2000 | 728 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1997 | 2687 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 1504 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1995 | 317 | 0.030 |
Why?
|
| Mentors | 1 | 2000 | 660 | 0.030 |
Why?
|
| Disease | 1 | 2000 | 672 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 1997 | 376 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 2169 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 384 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1995 | 555 | 0.030 |
Why?
|
| Program Development | 1 | 2000 | 1298 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 1994 | 316 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 1385 | 0.030 |
Why?
|
| Binding Sites | 3 | 1997 | 6055 | 0.030 |
Why?
|
| Teaching | 1 | 2000 | 1169 | 0.030 |
Why?
|
| CHO Cells | 1 | 1995 | 1388 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1997 | 3969 | 0.020 |
Why?
|
| Cricetinae | 1 | 1995 | 2425 | 0.020 |
Why?
|
| Patient Participation | 1 | 2000 | 1444 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 11902 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 2469 | 0.020 |
Why?
|
| Biological Transport | 1 | 1995 | 2092 | 0.020 |
Why?
|
| Internet | 1 | 2002 | 3092 | 0.020 |
Why?
|
| Risk | 1 | 2001 | 9612 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 801 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1995 | 13449 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2000 | 2374 | 0.020 |
Why?
|
| Pancreas | 1 | 1995 | 1690 | 0.020 |
Why?
|
| Protein Binding | 2 | 1997 | 9352 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 1444 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 17644 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2000 | 3249 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12330 | 0.020 |
Why?
|
| Curriculum | 1 | 2000 | 3741 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2004 | 5335 | 0.020 |
Why?
|
| Antigens | 1 | 1992 | 1446 | 0.020 |
Why?
|
| Base Sequence | 2 | 1995 | 12450 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 138 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3734 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 18964 | 0.020 |
Why?
|
| Multipotent Stem Cells | 1 | 2007 | 200 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2000 | 4793 | 0.010 |
Why?
|
| Mesoderm | 1 | 2007 | 673 | 0.010 |
Why?
|
| Animals | 5 | 2007 | 168441 | 0.010 |
Why?
|
| Rats | 2 | 1995 | 23742 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 6032 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3779 | 0.010 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 1994 | 17 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1994 | 115 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1994 | 94 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 9535 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1994 | 365 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7584 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1994 | 664 | 0.010 |
Why?
|
| Mutation | 2 | 1995 | 30045 | 0.010 |
Why?
|
| Conalbumin | 1 | 1992 | 5 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 2748 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 1762 | 0.010 |
Why?
|
| Clone Cells | 1 | 1992 | 1659 | 0.000 |
Why?
|
| Kinetics | 1 | 1994 | 6374 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 3076 | 0.000 |
Why?
|
| Middle Aged | 1 | 2021 | 220826 | 0.000 |
Why?
|
| Ligands | 1 | 1992 | 3271 | 0.000 |
Why?
|
| Mice | 2 | 2007 | 81509 | 0.000 |
Why?
|
| Male | 1 | 2021 | 360736 | 0.000 |
Why?
|
| Female | 1 | 2021 | 392581 | 0.000 |
Why?
|